WesBanco Bank’s Supernus Pharmaceuticals SUPN Stock Holding History

WesBanco Bank’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,300	Closed	-$217K	–	524
2018 Q3	$217K	Sell	4,300 -700	-14%	-$34.6K	0.01%	494
2018 Q2	$299K	Hold	5,000	–	–	0.02%	452
2018 Q1	$229K	Buy	+5,000	New	+$209K	0.01%	485

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

WesBanco Bank's SUPN Position: Q4 2018 in Review

WesBanco Bank sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 4,300 shares — an estimated $217K sold.

WesBanco Bank first reported a position in SUPN in Q1 2018 and held it in 3 quarters. The position peaked at $299K in Q2 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

WesBanco Bank reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
WesBanco Bank sold 4,300 Supernus Pharmaceuticals shares in Q4 2018, an estimated $217K.
WesBanco Bank first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 3 quarters.
WesBanco Bank's Supernus Pharmaceuticals position peaked at $299K in Q2 2018.
274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on WesBanco Bank's 13F filing for Q4 2018, filed 5 Feb 2019.